Healio
SearchLoading
Healio
SearchLoading
thin banner showing veins in the human eye

Euretina Congress
ByDavid Almeida, MD, MBA, PhD
ByMichela Cimberle
Fact checked byChristine Klimanskis, ELS

Read more

October 30, 2023
2 min watch
Save

VIDEO: Real-world data show good outcomes of fluocinolone acetonide implant

ByDavid Almeida, MD, MBA, PhD
ByMichela Cimberle
Fact checked byChristine Klimanskis, ELS

In this Healio Video Perspective, David Almeida, MD, MBA, PhD, speaks about real-world study results of the fluocinolone acetonide intravitreal implant, a long-acting drug delivery system for diabetic macular edema.

In the study, presented at the Euretina congress, patients were shown to do well with Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg, Alimera Sciences), irrespective of starting vision, with no new safety signals and significantly reduced treatment burden.

Sources/Disclosures

Collapse
Source:

Almeida D. 0.19 mg fluocinolone acetonide (FAc) implant leads to superior vision-, anatomical-, and treatment burden-related outcomes in eyes with better baseline visual acuity (≥20/40). Presented at: Euretina congress; Oct. 5-8, 2023; Amsterdam.

Disclosures: Almeida reports being a consultant, speaker and investigator for Alimera Sciences.

Read more from Euretina Congress

View all

Read more about

drug delivery system
fluocinolone acetonide
 

Related Content